A clinical trial called OrigAMI-4 has shown promise in shrinking cancerous head and neck tumors, according to research presented to the 2025 conference of the European Society for Medical Oncology in Berlin.
New Drug Shows 45% Overall Response Rate in Head, Neck Cancer Trial